The HIV prevention market will more than triple over the 2020–29 forecast period, with sales in the US, Japan, and five major European markets (France, Germany, Italy, Spain, and the UK) growing from $2.8bn to $9.7bn at a compound annual growth rate (CAGR) of 14.7%. This growth will be driven by continued penetration of the at-risk population and a diversification of approved therapies available for HIV prevention.

This Datamonitor Healthcare report contains a Patient-Based Forecast module.